Skip to main content
. 2019 Nov 19;62(24):11035–11053. doi: 10.1021/acs.jmedchem.9b00742

Table 3. Characterization of Compounds 3743 in hCCR2 and hCCR5a.

graphic file with name jm9b00742_0008.jpg

      hCCR2 hCCR5
compd R1 R3 pKi ± SEM (Ki, nM)b pIC50 ± SEM (IC50, nM) or inhibition at 1 μM (%)c
37 3,4-diCl cPr 9.35 ± 0.05 (0.4) 6.67 ± 0.03 (214)
38 3,4-diCl iPr 9.22 ± 0.05 (0.6) 6.91 ± 0.09 (132)
39 2,3-diCl iPr 8.81 ± 0.07 (1.6) 7.09 ± 0.07 (84)
40 2,5-diCl iPr 7.65 ± 0.03 (22.5) 20%
41 3,5-diCl iPr 8.66 ± 0.05 (2.2) 6.49 ± 0.06 (336)
42 3,5-diBr iPr 8.68 ± 0.01 (2.1) 64%
43 3-Br, 4-Cl iPr 9.42 ± 0.02 (0.4) 6.95 ± 0.04 (115)
a

Data are presented as mean pKi/pIC50 ± standard error of the mean (SEM) and mean Ki/IC50 (nM) of at least three independent experiments performed in duplicate.

b

pKi values from the displacement of ∼6 nM [3H]-CCR2-RA-[R] from U2OS cells stably expressing CCR2, at 25 °C.

c

Percent inhibition of β-arrestin recruitment in U2OS cells stably expressing CCR5 by 1 μM compound, in the presence of CCL3 (pEC80 = 7.9). pIC50 values were determined for compounds displaying more than 70% inhibition. % Inhibition values are presented as mean values of at least two independent experiments, performed in duplicate.